Unichem Labs bags USFDA nod for Bipolar disorder drug
New Delhi: Unichem Laboratories Limited today announced that the company has received Abbreviated New Drug Application (ANDA) approval for its Quetiapine Extended-Release Tablets USP, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg from the United States Food and Drug Administration (USFDA).
The product is a generic version of SEROQUEL XR (Quetiapine) Tablet, Extended Release, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg of AstraZeneca Pharmaceuticals LP.
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD).
The product will be commercialized from Unichem's Goa Plant.
Read also: Unichem Labs bags USFDA nod for Labetalol Hydrochloride Tablets
Medical Dialogues team had earlier reported that the company had received approval from the United States Food and Drug Administration (USFDA) for its schizophrenia pill Aripiprazole Tablets. Aripiraprazole tablets are indicated for schizophrenia and irritability associated with autistic disorders.
Read also: Unichem Labs Chairman says pharma sector recovery may get delayed but not derailed
Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Read also: Unichem Laboratories gets USFDA approval for its Nebivolol Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.